Rumiantsev D O, Piotrovskiĭ V K, Riabokon' O S, Metelitsa V I, Kokurina E V
Farmakol Toksikol. 1986 May-Jun;49(3):78-83.
The pharmacokinetics of nifedipine and its primary metabolite 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine carboxylate was studied in 7 patients with angina of effort after a single oral administration of nifedipine ("Corinfar" tablets) in doses of 20 and 30 mg. The binding of nifedipine and its metabolite to blood serum proteins was determined. Nifedipine appeared in the blood serum of the patients 1.5-2 hrs after the drug intake, the maximal serum concentration was observed 1.13 hrs after the intake. The mean half-life period of nifedipine in the serum was 4.51 hrs. With an increase of the nifedipine dose, its pharmacokinetics underwent linear changes. Nifedipine and its metabolite were not detected in the urine. Binding to the blood serum proteins was 97.4% for nifedipine and 90.5% for its metabolite. 20 mg of nifedipine is suggested to be insufficient for the creation of the effective drug concentration in the blood.
对7例劳力性心绞痛患者单次口服20毫克和30毫克硝苯地平(“康尔心”片)后,研究了硝苯地平及其主要代谢产物2,6 - 二甲基 - 4 -(2 - 硝基苯基)- 3,5 - 吡啶羧酸酯的药代动力学。测定了硝苯地平及其代谢产物与血清蛋白的结合情况。服药后1.5 - 2小时,硝苯地平出现在患者血清中,服药后1.13小时观察到血清浓度最高。硝苯地平在血清中的平均半衰期为4.51小时。随着硝苯地平剂量增加,其药代动力学呈线性变化。尿液中未检测到硝苯地平及其代谢产物。硝苯地平与血清蛋白的结合率为97.4%,其代谢产物为90.5%。建议20毫克硝苯地平不足以在血液中产生有效的药物浓度。